Alemtuzumab (MabCampath®) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000420
English
Authors' recommendations:
Alemtuzumab (MabCampath®) is recommended for restricted use within NHS Wales for the treatment of patients with B-cell chronic lymphocytic leukaemia (B-CLL) for whom fludarabine combination chemotherapy is not appropriate.
Alemtuzumab (MabCampath®) should be restricted for use in patients with previously untreated B-CLL with the cytogenetic abnormality 17p-deletion.
Alemtuzumab (MabCampath®) is not suitable for shared care within NHS Wales.
Details
Project Status:
Completed
Year Published:
2008
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=111767&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Leukemia, Lymphocytic, Chronic, B-Cell
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.